Endo Sees Drug Shortages Because of Novartis Plant Shutdown
This article is for subscribers only.
Endo Pharmaceuticals Holdings Inc., maker of the Opana ER painkiller, said there will be shortages of the drug while the plant that makes it is closed for improvements.
Some other analgesics produced there may also experience supply disruptions, Chadds Ford, Pennsylvania-based Endo said in a statement today. Novartis AG operates the factory, and the halt is meant to lower the chances of product packaging mix-ups.